Akebia Therapeutics (AKBA) Amortization of Deferred Charges (2013 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Amortization of Deferred Charges data on file, last reported at $4.6 million in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 26.8% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $20.1 million, a 5.98% increase from a year earlier, with the FY2025 full-year figure at $21.8 million, up 66.87% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $4.6 million, down from $4.8 million in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for AKBA reached as high as $7.2 million in Q3 2024 and fell as low as -$3.5 million in Q4 2023.
• Historically, Amortization of Deferred Charges has averaged $2.3 million across 5 years, with a median of $654000.0 in 2022.
• Across the five-year window, Amortization of Deferred Charges tumbled 642.2% in 2023 and jumped 6475.26% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $654000.0 in 2022, then tumbled by 642.2% to -$3.5 million in 2023, then soared by 257.76% to $5.6 million in 2024, then decreased by 15.05% to $4.8 million in 2025, then slipped by 3.68% to $4.6 million in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $4.6 million in Q1 2026, $4.8 million in Q4 2025, and $4.6 million in Q3 2025.